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Clostridium difﬁcile infection is the main cause of healthcare-
acquired diarrhea in the developed world. In addition to the
main virulence factors toxin A and B, epidemic, PCR Ribo-
type 027 strains, such as R20291, produce a third toxin, CDT.
To develop effective medical countermeasures, it is important
to understand the importance of each toxin. Accordingly, we
created all possible combinations of isogenic toxin mutants of
R20291 and assessed their virulence. We demonstrated that
either toxin A or toxin B alone can cause fulminant disease in
the hamster infection model and present tantalizing data that
C. difﬁcile toxin may also contribute to virulence.
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Two large cytotoxins, toxins A and B, remain the only deﬁni-
tive virulence factors of Clostridium difﬁcile. Their relative im-
portance in C. difﬁcile infection (CDI), however, remains a
subject of debate. Early studies were hampered by a dearth of
available genetic tools with which the stable isogenic mutants
required for comparative virulence studies could be created.
This obstacle was removed by the development, and later
reﬁnement, of ClosTron technology [1].
To date, 2 independent studies have investigated the relative
role of toxins A and B in virulence through the creation of iso-
genic toxin mutants and their analysis in the hamster infection
model. With respect to toxin A, conﬂicting results were ob-
tained: one study demonstrated that toxin A alone could not
cause disease in hamsters, whereas the other showed that an
equivalent mutant in the same animal model was virulent [2,
3]. In both cases, the mutants were generated in erythromycin-
susceptible derivatives of strains 630. Because these strains were
independently isolated following repeated serial passage in an-
tibiotic-free medium, the emergence of ancillary mutations that
could have inﬂuenced virulence cannot be discounted.
It has been suggested that this apparent paradox could be re-
solved by the examination of other strains [4], particularly poly-
merase chain reaction (PCR) ribotype 027 epidemic strains
(also referred to as 027/NAP1/B1 strains), that are associated
with more severe disease, higher relapse rates, increased mortal-
ity, and greater resistance to ﬂuoroquinolone antibiotics [5].
PCR ribotype 027 strains additionally produce a binary toxin,
called C. difﬁcile toxin (CDT). A role for CDT in virulence has
yet to be established. It shares similarity with Clostridium
perfringens iota toxin and has an adenosine diphosphate–
ribosyltransferase activity that covalently modiﬁes cell actin.
CDT, however, shows no cytotoxicity toward Vero cells without
prior trypsinization and has no adverse effects when puriﬁed
and injected into mice. [6] Yet, CDT protein levels were shown
to be much higher when measured in situ than when tested in
vitro [7]. By use of in vitro assays, it has additionally been
shown that puriﬁed binary toxin mediates increased adherence
of C. difﬁcile to epithelial cells through the formation of protru-
sions [8]. This suggests a role for binary toxin in adherence and
colonization. In the current investigation, we focused on the
creation and testing of isogenic toxin mutants in the PCR ribo-
type 027 strain R20291, an isolate epidemic in the United
Kingdom that was responsible for 2 outbreaks of CDI at the
Stoke Mandeville hospital in 2003 and 2004.
METHODS
Strains and Growth Conditions
Escherichia coli strains used were TOP10 (Invitrogen) as a
cloning host and E. coli CA434 [9] as a conjugal donor. C. difﬁ-
cile strains used were R20291 and mutants. E. coli cultures were
aerobically grown with shaking on Luria Bertani medium at
37°C unless stated otherwise. C. difﬁcile cultures were cultivated
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in BHIS [3] or TY [3] at 37°C in an anaerobic workstation
(Don Whitley Scientiﬁc, Shipley, United Kingdom). Antibiotics
used in this study are detailed in the Supplementary Materials.
Molecular Biology Techniques
Qiagen mini prep kits were used to purify plasmids. Genomic
DNA was obtained by phenol-chloroform extraction. Digests,
PCRs, and DNA puriﬁcation were undertaken according to
general protocols [10]. DNA Sanger sequencing was performed
by Source Biosciences (Nottingham, United Kingdom).
Construction and Characterization of Mutants
The following C. difﬁcile single-mutant strains were made from
the parental strain R20291, using ClosTron technology as de-
scribed elsewhere [11]: tcdA−, tcdB+, cdtA+ (A−B+C+); tcdA+,
tcdB−, cdtA+ (A+B−C+); and tcdA+, tcdB+, cdtA− (A+B+C−).
The tcdA−, tcdB−, cdtA+ (A−B−C+) double-mutant strain was
made from the A+B−C+ mutant, using a catP-based ClosTron
and the pseudo-suicide vector principle [3]. The other 2 double
mutants were made from the A+B+C− mutant. The triple
mutant was made from the A−B−C+ double mutant. Retargeted
plasmids and primers used to verify insertions are listed in the
Supplementary Materials.
Southern and Western Blots
Southern and Western blots were performed as described previ-
ously [3].
Resequencing of ClosTron Mutants
Genomic DNA of the created toxin mutants was isolated and
subjected to Illumina sequencing (GATC). The obtained se-
quences were mapped to R20291 National Center for Biotech-
nology Information accession number NC_013316.1 and then
analyzed for single-nucleotide polymorphisms (SNPs) and in-
sertions and deletions (InDels), using CLC-bio.
Cell Toxicity Assays
Cell cytotoxicity assays were performed as previously described [3].
Hamster Infection Model
We used a block design with ﬁnal group sizes of 8–10 animals.
Female golden Syrian hamsters (weight, 100–130 g) were
housed singly in individually ventilated cages. Each hamster re-
ceived an oral dose of clindamycin (30 mg/kg) 7 days before
being infected orally with 104 C. difﬁcile spores. Hamsters were
monitored 3–4 times/day after infection and were assessed for
several parameters, including presence and severity of diarrhea,
weight loss, level of activity, starey coat, sunken eyes, hunched
posture, and response to stimulus. A scoring system based on
the severity of changes observed (ranging from 0 to 3 for each
parameter) was used to quantify changes in the condition of
the animals, which were euthanized when a predetermined cu-
mulative value was reached. The hamsters were handled
individually in a microbiological safety cabinet. In line with
United Kingdom Home Ofﬁce and local ethics review board re-
quirements to reduce animal suffering, an alternative to death
was used as the end point [3].
Fecal pellets were collected daily and plated to determine the
presence of C. difﬁcile. Cecum samples from each hamster were
homogenized and plated, and C. difﬁcile counts were deter-
mined. PCR was performed to determine the genotype of each
strain recovered from hamsters (Supplementary Materials).
RESULTS AND DISCUSSION
Throughout this study, the insertion of a group II intron, using
ClosTron technology, into the targeted gene was conﬁrmed by
the nucleotide sequencing of DNA fragments, generated by
PCR, that span the intron junctions. The absence of insertion
at secondary sites was conﬁrmed by Southern blot, and func-
tional inactivation of the respective toxin genes was shown by
appropriate Western blots (Supplementary Figure 1). The
genomes of the created mutants were resequenced and shown
to harbor no additional mutations (SNPs and InDels) to those
intended.
Strain R20291 produces CDT in addition to toxins A and
B. As the primary goal of our study was to examine the relative
roles of toxins A and B in CDI, we initially undertook all our
studies in strains in which the binary toxin had been inactivated
by a ClosTron-derived insertion in the cdtA gene encoding for
the catalytic domain of the toxin. Hereafter, toxin A will be re-
ferred to as “A,” toxin B as “B,” and CDT as “C.” A “+” indi-
cates that the gene is still intact and, hence, that the toxin is
produced, whereas a “−” indicates that the respective gene has
been interrupted and that the corresponding toxin is no longer
produced. Accordingly, mutants were generated producing
either toxin A (A+B−C−) or toxin B (A−B+C−) alone or neither
(A−B−C−). The toxicity of the 3 mutant strains created was ini-
tially measured using a cytotoxicity assay on HT29 (human
colon carcinoma) cells and Vero (African green monkey
kidney) cells. The strain only producing toxin B (A−B+C−) still
displayed a level of cytotoxicity similar to that of the wild-type
strain (A+B+C+), whereas the strain only expressing toxin A
(A+B−C−) showed attenuated toxicity (Vero cell assay, P < .05)
(Figure 1). The triple mutant (A−B−C−) displayed no cytotox-
icity. Thereafter, the in vivo virulence of all 3 mutants was com-
pared to that of the wild-type strain in the hamster infection
model. A total of 8–10 female golden Syrian hamsters were in-
fected orally with 104 spores of the respective strains and moni-
tored for signs of CDI. Changes in condition were regularly
scored [3], and the experiment was terminated when hamsters
developed fulminant CDI, as described by Kuehne et al [3].
The experiment duration was 14 days.
As expected, all hamsters that were colonized with the
wild-type R20291 strain (9 of 10 infected were colonized)











succumbed to the disease in a mean time (±SD) of 3.7 ± 1.97
days after infection (Figure 2). All 8 hamsters infected and colo-
nized with the triple toxin mutant strain (A−B−C−) survived
for the duration of the experiment and showed no signs or
symptoms of CDI. In contrast, all of the hamsters (8 of 8) that
were infected and then colonized with a strain making only
toxin B (A−B+C−) succumbed to CDI, with a mean time (±SD)
from infection to end point of 2.3 ± 0.52 days. Crucially, all
hamsters (7 of 9) infected and then colonized with a strain only
making toxin A (A+B−C−) also developed clinical signs of CDI,
with a mean interval (±SD) of 5.9 ± 1.98 days from infection to
end point. These data are entirely consistent with the equiva-
lent experiments conducted previously with mutants generated
in strain 630Δerm; that is to say, an isogenic strain producing
toxin B alone is more virulent than an isogenic strain produc-
ing only toxin A (P < .05), but the latter is still able to cause
disease in hamsters. Given the unknown role of CDT in
disease, we created a further series of toxin A and B mutants in
which the binary toxin genes were still functional. Unsurpris-
ingly, the toxin A and B mutants with this C+ background
(A−B−C+) were nontoxigenic under the experimental condi-
tions used in vitro. The strains still expressing toxin B and CDT
(A−B+C+) and those expressing toxin A and CDT (A+B−C+)
showed high levels of cytotoxicity, although levels in the latter
case were slightly less than those for the wild-type strain (Vero
cell assay, P < .05). When tested in vivo, it was noted that all of
the hamsters (8 of 8) infected and colonized with the single
toxin A (A−B+C+) and toxin B mutants (A+B−C+) developed
terminal CDI, with mean intervals (±SD) of 2.7 ± 2.53 days and
3.0 ± 1.61 days from infection to end point, respectively. Partic-
ularly striking was the apparently increased virulence (P < .05)
of the A+B−C+ mutant (mean time from infection to end point,
3.0 days), compared with that of the A+B−C− mutant (mean
time from infection to end point, 5.9 days), suggesting that the
presence of CDT may accentuate the virulence of a toxin B
mutant strain producing toxin A alone. Thus, CDT may act in
concert with toxin A to increase virulence.
It is worth noting that the hamsters infected with some
single-mutant strains succumbed earlier, on average, to disease
than hamsters infected with the wild-type strain. A likely expla-
nation for this is the introduction of the ermB gene (through
the mutagenesis procedure) into the chromosome of the
Figure 1. In vitro cytotoxicity. Supernatants of the parental strain R20291 and the 7 mutants, A−B+C+, A + B−C+, A−B−C+, A−B+C−, A+B−C−, and
A−B−C− (see Methods for deﬁnitions), were used in cell culture assays to measure cytotoxicity. HT29 cells (A) and Vero cells (B) were cultured to a ﬂat
monolayer before adding Clostridium difﬁcile supernatants in 4-fold dilutions series. After a 24-hour incubation period, toxin end point titers were deter-
mined. Data represent mean values ± SD; n = 3. Statistical analyses were performed using 1-way analysis of variance, followed by Dunnett’s multiple com-
parison test. *P < .05.
Figure 2. Virulence of Clostridium difﬁcile strains in hamsters. Groups
of 8–10 hamsters were challenged with C. difﬁcile R20291 (A+B+C+) or
one of the toxin mutant strains, A−B+C−, A+B−C−, A−B−C−, A−B+C+,
A + B−C+, or A−B−C+ (see Methods for deﬁnitions). The time from infec-
tion to end point is presented in days. The duration of the experiment was
set at 14 days. Statistical analyses were performed using 1-way analysis
of variance and the Student t test. *P < .05.











mutants, which confers resistance to clindamycin. Because the
wild-type strain is susceptible to clindamycin, the use of this
antibiotic in the infection procedure may have affected the
ability of this strain to colonize efﬁciently.
Intriguingly, in the case of the double toxin mutant
(A−B−C+; ie, an isogenic mutant producing only CDT), 3 of 9
animals succumbed to disease (Figure 2). It should, however,
be emphasized that these 3 animals did not show typical symp-
toms of CDI. Rather than producing loose feces and having a
cecum with diffuse hemorrhage, they only showed signs of wet
tail. Furthermore, we observed some hemorrhage and inﬂam-
mation in their small intestines, which was not seen in any
other animals. These observations are in keeping with a previ-
ous suggestion that C. difﬁcile can cause infection of the small
intestine [12]. Moreover, it has previously been shown that
binary toxin can cause enterotoxic effects in the rabbit ileal
loop assay [13]. This could point to a role of binary toxin in C.
difﬁcile virulence.
In conclusion, our studies reafﬁrm the previous ﬁnding that
isogenic virulent strains of C. difﬁcile producing toxin A alone
cause disease in the hamster and reenforce our view that the de-
velopment of diagnostic tests, vaccines, and therapeutics should
focus on both toxin A and toxin B. Our experiments have also
produced tantalizing evidence that CDT may contribute to
disease. It has previously been suggested that the presence of
binary toxin is linked to more severe disease outcomes [14], a
view further supported by McEllistrem et al [15]. Moreover, the
presence of CDT in all representatives of certain so-called hy-
pervirulent strains (eg, PCR ribotype 027 and ribotype 078
strains) provides additional compelling evidence that it contrib-
utes to virulence. Further research will be necessary before the
role of CDT in disease is fully understood, but in the meantime
it may be prudent to test for its presence in clinical isolates
through appropriate diagnostic tests.
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